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Abstract. We assessed the effect of mass azithromycin treatment on malaria parasitemia in a trachoma trial in Niger.
Twenty-four study communities received treatment during the wet, high-transmission season. Twelve of the 24 com-
munities were randomized to receive an additional treatment during the dry, low-transmission season. Outcome mea-
surements were conducted at the community-level in children < 1–72 months of age in May–June 2011. Parasitemia was
higher in the 12 once-treated communities (29.8%, 95% confidence interval [CI] = 21.5–40.0%) than in the 12 twice-
treated communities (19.5%, 95% CI = 13.0–26.5%, P = 0.03). Parasite density was higher in once-treated communities
(354 parasites/mL, 95% CI = 117–528 parasites/mL) than in twice-treated communities (74 parasites/mL, 95% CI = 41–202
parasites/mL, P = 0.03). Mass distribution of azithromycin reduced malaria parasitemia 4–5 months after the interven-
tion. The results suggest that drugs with antimalaria activity can have long-lasting impacts on malaria during periods
of low transmission.
INTRODUCTION
The World Health Organization (WHO) currently recom-
mends repeated mass oral azithromycin distributions in
trachoma-endemic areas to control the ocular strains of
Chlamydia that cause the disease. A cohort study and a
cluster-randomized trial have showed that these distribu-
tions could reduce childhood mortality.1,2 Cohort studies have
suggested that azithromycin may reduce leading causes of
childhood mortality, including respiratory disease, diarrhea,
and malaria.3–7 In areas with seasonal malaria transmission,
repeated administration of antimalarial drugs to children during
the transmission season (intermittent preventive therapy of
children [IPTc])8,9 has been shown to reduce malaria transmis-
sion, although preventive therapy outside of the transmission
season is not typically recommended.3 However, transmission
models suggest treatment during the low-transmission season
of an infectious disease may provide significant or even
maximum impact.10–12 Azithromycin has antimalaria activity,
although lower than first-line agents.13–15 It is not clear
whether mass administration of azithromycin during the low
malaria transmission season could have a long-lasting anti-
malaria effect.
In a large, cluster-randomized clinical trial for trachoma,
we assessed whether mass oral azithromycin distributions
reduced malaria parasitemia and increased hemoglobin con-
centration.16 We compared community-level malaria asexual
parasitemia, parasite density and gametocytemia, and the
hemoglobin concentration in communities randomized to a
single mass treatment with azithromycin at the beginning of
the rainy season to that in communities randomized to this
treatment plus a second azithromycin distribution during the
dry season.
METHODS
Study design. The Program for the Rapid Elimination of
Trachoma (PRET) is a set of three cluster-randomized trials
in Niger, Tanzania, and the Gambia.16,17 In the Niger trials,
48 grappes (government health units, termed communities in
this report) were randomized into 4 arms of 12 grappes each
to evaluate different treatment frequencies and treatment
coverage levels (Figure 1). Inclusion criteria for the commu-
nities have been described and included total population
on the last census between 250 and 600 persons and preva-
lence of active trachoma (trachomatous inflammation fol-
licular, by using the WHO system)18 ³ 10% in children
< 1–72 months of age.16 We conducted a malaria assess-
ment in 24 communities from 2 of the 4 PRET study arms
during May–June 2011.
Intervention. Twelve communities were randomized to
receive a single mass distribution of oral azithromycin to all
persons ³ 6 months of age, and 12 communities were random-
ized to receive a mass distribution of oral azithromycin in
children 6 months to 12 years of age plus a second distribution.
The treatment coverage goal was 80% of the targeted group.
The initial distribution of directly observed oral azithromycin
(height-based dosing approximating 20 mg/kg19,20) was given
to all eligible persons during July 3–August 9, 2010 in the
24 communities. The second mass treatment was provided only
to the 12 communities randomized to receive this intervention
during January 7–10, 2011. Thus, communities in the twice-
treated arm were randomized to an extra mass distribution in
the dry, low transmission season. During May 24–June 7, 2011,
a cross-sectional survey of 50 randomly chosen children
< 1–72 months of age was performed in all 24 communi-
ties. Because the selection of these 50 children was based on
the 12-month census, some of these children may not have
been present at the time of azithromycin distributions. If a
community contained < 50 children, all eligible children were
included, but note this is a community-randomized, intent-to-
treat analysis of direct and indirect effects of the antibiotic.
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Clinical and laboratory assessments. Thick blood smears
and blood spots of approximately 20 mL were prepared on
Whatman FTA Elute cards (GE Healthcare, Piscataway, NJ)
from a finger prick, after obtaining consent from a parent
or guardian. Blood spots were air-dried and stored at room
temperature in sealed plastic bags containing desiccant. The
thick blood smears were stained with 3% Giemsa and read
with a light microscope by two experienced microscopists at
the Zinder Hospital in Niger. The microscopists were masked
to community treatment assignment and to the readings of
the other microscopist. The malaria case definition was based
on the presence or absence of Plasmodium parasites on
microscopy slides. Parasite densities were determined from
thick blood smears by counting the number of asexual para-
sites per 200 leukocytes and assuming a leukocyte count
of 8,000/mL.21 Parasites were considered present if both
microscopists observed them. Because prevalence was low,
gametocytes were considered present if either microscopist
observed them.
To determine Plasmodium species, one thick blood smear–
positive case was randomly chosen from each of the 24 study
communities and tested for Plasmodium DNA by polymerase
Figure 1. Participant flow in cluster-randomized clinical trial in 24 communities in Niger.
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chain reaction (PCR). A 3-mm punch was prepared from a
blood spot (Harris Micro-Punch; Ted Pella, Inc., Redding,
CA), and DNA was extracted and eluted in 30 mL of sterile
water, according to the FTA card manufacturer’s instructions.
Between each sample, the micro-punch was cleaned with
bleach, rinsed with ethanol, and dried. A blank punch from a
clean FTA card was taken between each sample as a negative
control to test for cross-contamination.
For species determination, a portion of the cytochrome
b region was amplified by using nested PCR.22 The PCRs
were performed in 50-mL reactions using the TopTaq DNA
polymerase kit (QIAGEN, Valencia, CA) and 5 mL of the
extracted DNA (first round) or the amplicon (nested reac-
tion). The PCR products were confirmed after electropho-
resis on a 2% agarose gel. Products from samples positive
for the 815-basepair cytochrome b fragment were purified
by using the QIAquick PCR Purification Kit (QIAGEN)
and then sequenced in both directions with nested primers
(Sequetech, Mountain View, CA). Sequences were trimmed,
edited, and aligned by using Sequencher 5.0 (Gene Codes
Corp, Ann Arbor, MI) and then compared with reference
sequences for P. falciparum, P. vivax, P. malariae, and
P. ovale found in GenBank.23 Hemoglobin concentration
was determined for each child (HemoCue AB, A¨ngelholm,
Sweden). Repeat hemoglobin assessments were performed
on every tenth case to assess reproducibility.
Randomization. Communities in Niger are grouped by the
government into integrated health centers (Center de Sante´
Inte´gre´e [CSI]) for the organization and delivery of health
services. To ensure similar allocation of any community-level
predictors between the study arms before treatment, we
performed stratified blocked randomization of communities
within each CSI on clinical trachoma prevalence in children
(trachomatous inflammation follicular in children < 1–5 years
of age by using the WHO Simplified Grading System) as
described.16,18 Communities were divided into 12 strata based
on the 6 CSI and high or low prevalence of clinical trachoma
within the CSI. Randomization of communities to the treat-
ment arms and randomization of persons within communities
was performed as described.16
Statistical analysis and sample size. Azithromycin distribu-
tions and analyses were performed at the community level
because the randomization unit was the community and
infection in one person in a community is not independent
of infection in another. To account for any clustering, we
used the community prevalence of parasitemia as the unit of
analysis. Because the data were reduced to a single statistic
in each group, it is not possible to misrepresent the structure
of the covariance matrix. The null hypothesis for the pri-
mary analysis was that the prevalence of malaria parasitemia
was the same in both treatment arms. We estimated that
12 communities per arm would provide 80% power to
detect a 3% absolute difference in malaria parasitemia,
assuming a baseline prevalence of 10%, and using an
intraclass correlation coefficient (ICC) of 0.075.24 Hypotheses
were tested with the signed rank test, and the difference
between arms was assessed by using the Hodges-Lehmann
estimator (pseudomedian) and bootstrap (999 resamples) per-
centile 95% confidence intervals (CIs). The endpoints are
included in all reported 95% CIs. All analyses were per-
formed as intention-to-treat at the community level. Cal-
culations were performed with Mathematica 9.0 (Wolfram
Research, Champaign, IL), STATA 11 (StataCorp LP, Col-
lege Station, TX), and the statistical package R 2.12 (R
Foundation for Statistical Computing, Vienna, Austria).
Human participants and consent procedures. Ethical
approval for this study was obtained from the Committee
for Human Research of the University of California, San
Francisco and the Ethical Committee of the Niger Ministry
of Health. Verbal consent was deemed ethical because of
the high illiteracy rates in the study area and approved by
the institutional review board. Consent was obtained from the
community leaders before examination and from the child’s
parent or guardian at the time of examination. Verbal consent
was documented on the registration form for each study par-
ticipant before examination in the field. In addition, thumb-
prints were obtained for the baseline visit. The study was
carried out in accordance with the Declaration of Helsinki,
and registered as ClinicalTrials.gov NCT00792922.
RESULTS
Participants and treatment coverage. Forty-eight commu-
nities were enrolled in PRET-Niger, 24 of which were by
design included in this trial.16 Twelve communities were ran-
domized to receive a single mass treatment, and 12 were
randomized to receive 2 mass treatments, with a goal of
80% antibiotic coverage to the targeted group (Figure 1).
A total of 2,133 children < 1–72 months of age were treated
at baseline (1,117 in once-treated communities and 1,016 in
twice-treated communities), and 1,030 were analyzed at one
year (485 in once-treated communities and 545 in twice-
treated communities). No communities were missing or lost
to follow-up throughout the study. The mean azithromycin
coverage of children < 1–72 months of age based on the
12-month census was 80.4% (95% CI = 76.8–84.1%) for
the single treatment of the once-treated communities,
and 74.4% (95% CI = 69.4–79.3%) and 78.7% (95% CI =
74.5–82.7%) for the baseline and six-month treatments,
respectively, in the twice-treated communities. The total
number of children 6–72 months of age who received treat-
ment based on the 12-month census was 808 at baseline
(394 in once-treated communities and 414 in twice-treated
communities) and 409 at six months (in twice-treated com-
munities). Baseline and demographic characteristics were
comparable in communities randomized to receive one or
two treatments (Table 1).
Malariometric and blood indices. Malaria parasitemia was
measured by thick blood smear in children < 1–72 months of
Table 1
Baseline characteristics at time of enrollment of < 1–72-month-old
children in 24 communities in Niger*
Characteristic
Treatment arm
Once-treated,
n = 12 communities
Twice-treated,
n = 12 communities
Children per community 124 (42–207) 118 (88–147)
Age, mean months 30.8 (29.8–31.9) 31.9 (30.7–33.0)
Proportion female 51.3% (48.2–54.4%) 50.1% (47.1–53.1%)
Prevalence of clinical
trachoma TF†
26.5% (14.9–38.0%) 24.1% (15.9–32.3%)
Prevalence of clinical
trachoma TI†
8.6% (4.4–12.8%) 9.4% (4.9–14.0%)
*Values in parentheses are 95% confidence intervals.
†Trachomatous inflammation follicular (TF) and trachomatous inflammation intense (TI)
according to a World Health Organization simplified grading system.18
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age 4–5 months after the second azithromycin treatment.
In the Plasmodium speciation analysis, 22 of the 24 random
samples (92%) were positive for the Plasmodium cyto-
chrome b region. The 24 blank control punches (negative
controls) corresponding to each sample were PCR negative.
Sequencing of the Plasmodium cytochrome b showed that
22 (100%) of the positive samples were P. falciparum (100%,
97.5% CI = 85–100%).
Parasitemia grades were concordant between the two micros-
copists in 94% of samples and had an ICC of 0.985 (95% CI =
0.967–0.995). The community-level Hodges-Lehmann esti-
mators and 95% CIs for all measurement in the two arms
are shown in Table 2. The community-level prevalence of
parasitemia was 10.2% lower (95% CI = 0.5–22.7% lower)
in the twice-treated communities than in the once-treated
communities (P = 0.03). As sensitivity analysis, we separately
repeated the analysis with grader 1 only, grader 2 only, and if
either grader-observed parasites. As another sensitivity anal-
ysis, we performed logistic regression by using study arm as a
fixed effect and community as a random effect. This regres-
sion showed that children who received an additional anti-
biotic treatment were significantly less likely to have malaria
parasitemia observed on thick blood smear (odds ratio =
0.52, 95% CI = 0.29–0.95, P = 0.03). Community-level para-
site density was 232 parasite/mL (95% CI = 17–455 para-
sites/mL) lower in the twice-treated communities than in the
once-treated communities (P = 0.03). Community-level
gametocytemia was 2.0% lower (95% CI = 0.0% lower inclu-
sive to 6.2% lower) in the twice-treated communities than in
the once-treated communities, although the low prevalence
may have precluded demonstrating a significant difference
between study arms if one exists (P = 0.29). The ICC for
repeat measurement of hemoglobin was 0.960 (95% CI =
0.886–0.994). Community-level hemoglobin was 17.7% higher
(95% CI = 28.6% lower to 64.6% higher) in the twice-treated
communities than in the once-treated communities (P = 0.11).
DISCUSSION
In this cluster-randomized trial, communities randomized
to receive an extra mass distribution of oral azithromycin
during the low malaria transmission season had reduced
malaria parasitemia and parasite density 4–5 months later
than communities randomized to receive only a single distri-
bution. We were unable to demonstrate a significant differ-
ence in gametocytemia or hemoglobin concentration associated
with the extra mass treatment, although gametocytemia was
lower and hemoglobin levels were higher in the twice-
treated communities.
Although azithromycin has antimalaria activity, it is not as
potent as many standard antimalaria agents and, as with other
antibiotics for malaria (e.g., tetracyclines and clindamycin),
has a slow action.25 For treatment of malaria, azithromycin
has shown excellent efficacy against P. vivax and modest effi-
cacy against P. falciparum in areas with limited immunity.15
In two individual-randomized trials, azithromycin demon-
strated a range of preventive efficacy of 64–83% against
falciparum malaria, but this was less than that of first-line
agents.13,15 Azithromycin may nonetheless play some role in
malaria control because it has a long half-life, is well tolerated,
and is approved for use in children and pregnant women.26–28
Furthermore, azithromycin is distributed on such a large scale
for trachoma that even a modest effect could be of interest.
The IPTc has been widely advocated for the control of
malaria in Africa, and it has shown efficacy when administered
during the wet, high-transmission season in areas with highly
seasonal malaria transmission.9,29 Combination therapies for
IPTc such as amodiaquine plus sulfadoxine-pyrimethamine or
artesunate plus sulfadoxine-pyrimethamine have been effec-
tive in areas of seasonal malaria transmission.9,29,30 Emerging
antimicrobial drug resistance has spread through malaria-
endemic areas and has made treatment difficult.31 We did not
measure resistance to azithromycin in Plasmodium because
we were unable to perform cultures at our field site and bio-
chemical assays for this have not been adequately described.
To the best of our knowledge, resistance to antibiotics has
not been demonstrated in malaria except to antifolates.32
Nevertheless, surveillance for resistance in malaria is impor-
tant to track whenever any malaria therapy is used.
Transmission models suggest treatment during the low
transmission season of an infectious disease may provide
significant or even maximum impact.10,12 For malaria, this
may be because circulating malaria parasites that are elimi-
nated with mass treatment are not replaced in the absence
of transmission.10 Mass drug administration before the
malaria transmission season prevents parasite prevalence
levels from recovering to their pretreatment levels, and this
raises the probability of parasite elimination in these low
transmission settings.12 Mathematical models of mass treat-
ment of another seasonal disease (trachoma) imply that the
optimal time for treatment to achieve elimination may be
during the season of lowest transmission.11 Seasonal varia-
tions in transmission might be able to be exploited to maxi-
mize the impact of treatment.12
This cluster-randomized trial, designed to monitor trachoma,
can be applied to secondary questions such as the effect of
azithromycin distributions on malaria. Malaria indices were
monitored at 12 months into the trial and provided a con-
venient means of comparing the impact of a single, low-
transmission season mass treatment with azithromycin. To
account for clustering, we used the prevalence of parasitemia
in a community rather than an individual-based analysis. This
design necessarily has some important limitations. It did not
enable detection of clinical malaria cases or the evaluation
of malaria during the subsequent rainy season. No assess-
ment of the prevalence of malaria parasitemia at baseline was
conducted. Inclusion of baseline prevalence as a covariate
may have offered a more powerful study design or provided
evidence that baseline measurements did not explain the
Table 2
Malariometric and blood indices in 24 communities in Niger
randomized to one mass azithromycin treatment or one mass
azithromycin treatment plus a second mass treatment in the dry,
low-transmission season in children ³ 6 months of age*
Measurement
Treatment arm
P
Once-treated,
n = 12 communities
Twice-treated,
n = 12 communities
Malaria parasitemia 29.8% (21.5–40.0%) 19.5% (13.0–26.5%) 0.03
Parasite density,
parasites/mL
354 (117–528) 74 (41–202) 0.03
Gametocytemia 1.5% (0–6.0%) 0% (0–1.5%) 0.29
Hemoglobin, g/dL 10.0 (9.8–10.2) 10.2 (10.0–10.4) 0.20
*All values were determined by using the Hodges-Lehmann estimator (pseudomedian).
Values in parentheses are 95% confidence intervals.
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observed association. However, the randomized post-test
design does permit valid inference33 because the treat-
ment assignments are stochastically independent of any
other explanatory covariate (including baseline malaria
parasitemia).34 Lack of baseline prevalence also makes it
impossible to know whether malaria parasitemia decreased
more in the twice-treated arm or simply increased less than
in the once-treated arm. The parasitemia outcome was
validated by two independent masked graders. However,
external monitors were not used and molecular techniques
were not used beyond the speciation analysis. In the twice-
treated arm, only children received antibiotics, whereas in
the once-treated arm, all ages were eligible. It is possible
that treating adults had an indirect effect on children,
and that this decreased the effect we observed with the
extra dose in the twice-treated arm. When the readings of
the two microscopists were discordant, we did not have a
third adjudicate. For the primary analysis, we assumed
positivity if both agreed. It should be noted that con-
cordance was extremely high, and that we obtained simi-
lar results in sensitivity analyses using only one grader or
assuming positivity if either grader observed parasites.
In summary, mass distribution of azithromycin provided
during the dry, low-transmission season in Niger was associated
with a reduced community prevalence of malaria parasitemia
and parasite density 4–5 months later. Gametocytemia and
hemoglobin concentration were not significantly different
after an additional dry season administration of azithromycin.
Mass administration of azithromycin was associated with
reduced mortality in Ethiopia,1,2 although it is unclear if this
finding was related to protection against malaria. Further
studies could address the impact of mass administration of
azithromycin on the incidence of clinical episodes of malaria,
severe malaria, and other health outcomes.
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